Сlostridium difficile Infection in a COVID-19 Patient

Aim. The clinical observation highlights plausible compound origins of diarrhoea, fever and neutrophilic leucocytosis in COVID-19 and the rationale to exclude Clostridium difficile infection in such patients.

Key points. A 57-yo female patient was admitted in May 2020 with the complaints of 39 °C fever, general weakness, polymyalgia, diarrhoea to 3–4 times a day (mushy stool, no morbid inclusions). Initial diarrhoea was non-severe and likely triggered by the coronavirus infection. A background antibiotic and putative-immunosuppressive therapy proceeded with watery diarrhoea to 7–8 times a day and C. difficile toxins A and B detected in stool. The C. difficile infection relapsed on day 10 of vancomycin withdrawal and associated with elevated body temperature, diarrhoea and neutrophil leucocytosis; signs of colitis determined in ultrasound and CT. Exacerbation was successfully treated in a repeated metronidazole-combined vancomycin course.

Conclusion. Patients with COVID-19 are at risk of clostridial colitis due to massive antibiotic, systemic glucocorticoid and biologics-based therapy they receive. The opportunistic bacterial infection of C. difficile often proceeds undetected due to its potential mirroring of COVID-19 presentation. A screening algorithm in COVID-19 patients with diarrhoea should imply steps for C. difficile detection.

1. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Temporary guidelines. Version 8 (03.09.2020). https://static-0.minzdrav.gov.ru/system/attachments/attach-es/000/051/777/original/030902020_COVID-19_v8.pdf (In Russ.)].

2. Ivashkin V.T., Yushchuk N.D., Mayev I.V., Lapina T.L., Poluektova Y.A., Shifrin O.S., et al. Diagnostics and treatment of Clostrid-ium difficile-associated disease: Guidelines of the Russian gastroenterological association. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(5):56–65 (In Russ.). DOI: 10.22416/1382-4376-2016-26-5-56-65

3. Yang L., Tu L. Implications of gastrointestinal manifestations of COVID-19. Lancet Gastroenterol Hepatol. 2020;5(7):629–30. DOI: 10.1016/S2468-1253(20)30132-1

4. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061–9. DOI: 10.1001/jama.2020.1585. Erratum in: JAMA. 2021 Mar 16;325(11):1113.

5. Rokkas T. Gastrointestinal involvement in COVID-19: a systematic review and meta-analysis. Ann Gastroenterol. 2020;33(4):355–65. DOI: 10.20524/aog.2020.0506

6. D’Amico F., Baumgart D.C., Danese S., Peyrin-Biroulet L. Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin Gastro-enterol Hepatol. 2020;18(8):1663–72. DOI: 10.1016/j.cgh.2020.04.001

7. Hamming I., Timens W., Bulthuis M.L., Lely A.T., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7. DOI: 10.1002/path.1570

8. Tang A., Tong Z.D., Wang H.L., Dai Y.X., Li K.F., Liu J.N., et al. Detection of Novel Coronavirus by RT-PCR in Stool Specimen from Asymptomatic Child, China. Emerg Infect Dis. 2020;26(6):1337–9. DOI: 10.3201/eid2606.200301

9. Hosoda T., Sakamoto M, Shimizu H, Okabe N. SARS-CoV-2 enterocolitis with persisting to excrete the virus for approximately two weeks after recovering from diarrhea: A case report. Infect Control Hosp Epidemiol. 2020;41(6):753–4. DOI: 10.1017/ice.2020.87. PMID: 32188528. PMCID: PMC7156577.

10. Mao R., Qiu Y., He J.S., Tan J.Y., Li X.H., Liang J., et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667–78. DOI: 10.1016/S2468-1253(20)30126-6. Erratum in: Lancet Gastroenterol Hepatol. 2020 Jul;5(7):e6.

11. Marra A.R., Perencevich E.N., Nelson R.E., Samore M., Khader K., Chiang H.Y., Chorazy M.L., et al. Incidence and Outcomes Associated With Clostridium difficile Infections: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(1):e1917597. DOI: 10.1001/jamanetworkopen.2019.17597

12. Steele J., Chen K., Sun X., Zhang Y., Wang H., Tzipori S., Feng H. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis. 2012;205(3):384–91. DOI: 10.1093/infdis/jir748

13. Steele J., Chen K., Sun X., Zhang Y., Wang H., Tzi-pori S., Feng H. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis. 2012;205(3):384–91. DOI: 10.1093/infdis/jir748

14. Rao K., Erb-Downward J.R., Walk S.T., Micic D., Falkowski N., Santhosh K., et al. The systemic inflammatory response to Clostridium difficile infection. PLoS One. 2014;9(3):e92578. DOI: 10.1371/journal.pone.0092578

15. Guerri S., Danti G., Frezzetti G., Lucarelli E., Pradella S., Miele V. Clostridium difficile colitis: CT findings and differential diagnosis. Radiol Med. 2019;124(12):1185–98. DOI: 10.1007/s11547-019-01066-0